Target Price | $9.67 |
Price | $1.14 |
Potential |
747.95%
register free of charge
|
Number of Estimates | 6 |
6 Analysts have issued a price target Werewolf Therapeutics Inc 2026 .
The average Werewolf Therapeutics Inc target price is $9.67.
This is
747.95%
register free of charge
$15.00
1,215.79%
register free of charge
$4.00
250.88%
register free of charge
|
|
A rating was issued by 6 analysts: 6 Analysts recommend Werewolf Therapeutics Inc to buy, 0 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Werewolf Therapeutics Inc stock has an average upside potential 2026 of
747.95%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -1.63 | -1.87 |
55.24% | 14.72% | |
P/E | negative |
4 Analysts have issued a Werewolf Therapeutics Inc forecast for earnings per share. The average Werewolf Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Werewolf Therapeutics Inc...
Analyst | Rating | Action | Date |
---|---|---|---|
Wedbush |
Locked
➜
Locked
|
Locked | May 09 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 12 2025 |
Wedbush |
Locked
➜
Locked
|
Locked | Mar 12 2025 |
JMP Securities |
Locked
➜
Locked
|
Locked | Jan 14 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 19 2024 |
Analyst Rating | Date |
---|---|
Locked
Wedbush:
Locked
➜
Locked
|
May 09 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 12 2025 |
Locked
Wedbush:
Locked
➜
Locked
|
Mar 12 2025 |
Locked
JMP Securities:
Locked
➜
Locked
|
Jan 14 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 19 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.